Skip to main content
. 2024 Apr 5;63(5):669–681. doi: 10.1007/s40262-024-01366-3

Fig. 1.

Fig. 1

Final model schematic for SG, free SN-38, and tAB. CLSG clearance of SG, CLSN38/F apparent clearance of free SN-38, CLtAB clearance of tAB, IV intravenous, KREL first-order release rate constant for free SN-38, QSG intercompartmental clearance of SG, QSN38/F apparent intercompartmental clearance of free SN-38, QtAB intercompartmental clearance of tAB, SG sacituzumab govitecan, tAB total antibody, V1SG central volume of distribution of SG, V2SG peripheral volume of distribution of SG, V1SN38/F apparent central volume of distribution of free SN-38, V2SN38/F apparent peripheral volume of distribution of free SN-38, V1tAB central volume of distribution of tAB, V2tAB peripheral volume of distribution of tAB